# A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct07662109` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07662109](<https://clinicaltrials.gov/study/NCT07662109>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07662109

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

## Technical summary

Registry record NCT07662109. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-06 (actual); primary completion 2028-07-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2000 participants (planned count; ClinicalTrials.gov record NCT07662109, source copy `cardio:ctgov-nct07662109-2026-10-30`, retrieved 2026-10-31)
- Started: 2026-07-06 (actual) (ClinicalTrials.gov record NCT07662109, source copy `cardio:ctgov-nct07662109-2026-10-30`, retrieved 2026-10-31)
- Primary completion: 2028-07-05 (anticipated) (ClinicalTrials.gov record NCT07662109, source copy `cardio:ctgov-nct07662109-2026-10-30`, retrieved 2026-10-31)
- Completion: 2028-07-05 (anticipated) (ClinicalTrials.gov record NCT07662109, source copy `cardio:ctgov-nct07662109-2026-10-30`, retrieved 2026-10-31)
- Countries: United States; Argentina; Brazil; China; Czechia; Denmark; Germany; Greece; Hungary; India; Japan; Malaysia; Mexico; Poland; Puerto Rico; Slovakia; South Africa; South Korea; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom; Vietnam (ClinicalTrials.gov record NCT07662109, source copy `cardio:ctgov-nct07662109-2026-10-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07662109-2026-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- Acronym: Eluminate-5
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Elecoglipron
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Elecoglipron-matched placebo
- Intervention (Drug): Dapagliflozin-matched placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 2e5e3bad83a0767b37e66197dda8e1f18429cd7db9f17be72d13cc3300c98831
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
